Search

Displaying results 1161 - 1170 of 5383 in total
  1. Drug

    Taliglucerase alfa

    go.drugbank.com/drugs/DB08876
    Approved

    It was approved in 2012 and is marketed under the name Elelyso for use in patients with type 1 Gaucher's disease.

  2. Drug

    Pemirolast

    go.drugbank.com/drugs/DB00885
    ApprovedWithdrawn

    As an ophthalmic aqueous sterile solution, pemirolast is used for the prevention of itching of the eyes caused by allergies such as hay fever, and allergic conjunctivitis.

  3. Drug

    Lumateperone

    go.drugbank.com/drugs/DB06077
    ApprovedInvestigational

    [L10902] Although there are several antipsychotics including [aripiprazole], [paliperidone] and [clozapine] available for clinical use, they are generally accompanied by significant metabolic and/or neurological … [A189093] Further, not only is the new antipsychotic selective for dopamine (D2) receptors in the mesolimbic and mesocortical brain regions, but it also has minimal off-target activity.

  4. Drug

    Secukinumab

    go.drugbank.com/drugs/DB09029
    ApprovedInvestigational

    [A249840] Following its first global approval in Japan in December 2014, secukinumab was approved by the European Commission on January 15, 2015, and by the FDA a few days after (January 21, 2015). … [L39600] By blocking the actions of IL-17A, secukinumab works to inhibit the pro-inflammatory pathways that drive immune-mediated inflammatory disorders.

  5. Drug

    Tegaserod

    go.drugbank.com/drugs/DB01079
    ApprovedWithdrawn

    [L5918,F4229] It was, however, voluntarily withdrawn from widespread use in the US market in 2007 after concerns arose over the possibility that tegaserod could potentially cause dangerous cardiovascular … Novartis' brand name Zelnorm (tegaserod) had originally received approval from the US FDA in 2002 for the treatment of irritable bowel syndrome with constipation (IBS-C).

  6. Drug

    Crinecerfont

    go.drugbank.com/drugs/DB18518
    ApprovedInvestigational

    [L51973] When administered alongside glucocorticoid replacement in patients with CAH it allows for the use of lower, physiological doses for glucocorticoid replacement, thereby reducing the risks associated … [A264818] Standard therapy involves cortisol replacement, but typically requires supraphysiological glucocorticoid doses to lower both ACTH and adrenal androgens, resulting in chronic glucocorticoid overexposure

  7. Drug

    Iomeprol

    go.drugbank.com/drugs/DB11705
    ApprovedInvestigational

    Iomeprol is a tri-iodinated, non-ionic radiographic contrast agent for intraarterial or intravenous use.

  8. Drug

    Glimepiride

    go.drugbank.com/drugs/DB00222
    ApprovedInvestigational

    [A177709] Glimepiride works by stimulating the secretion of insulin granules from pancreatic islet beta cells by blocking ATP-sensitive potassium channels (K<SUB>ATP</SUB> channels) and causing depolarization … [A177703] Glimepiride was approved by the Food and Drug Administration (FDA) in the United States in 1995 for the treatment of T2DM.

  9. Drug

    Turoctocog alfa pegol

    go.drugbank.com/drugs/DB14738
    ApprovedInvestigational

    It was developed by Novo Nordisk and approved by the US FDA on October 16, 2013 [L1104]. … Novo Nordisk's brand name Esperoct (turoctocog alfa pegol, N8-GP) was approved by the US FDA on February 19, 2019.

  10. Drug

    Plant-based virus-like particles, recombinant, adjuvanted COVID-19 vaccine

    go.drugbank.com/drugs/DB16757
    Approved

    The Covifenz COVID-19 vaccine (plant-based virus-like particles (VLP), recombinant, adjuvanted) is a plant-based vaccine developed in partnership by Medicago and GlaxoSmithKline which is approved in Canada